Howard H. Pai
Vancouver Island Centre
Victoria, BC, Canada
Victoria, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 21, 2026
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: October 16, 2024
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.
Journal: International journal of radiation oncology, biology, physics
Published: March 28, 2024
BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: October 26, 2023
Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: September 13, 2023
Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: September 11, 2023
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: August 07, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 09, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Journal: JAMA oncology
Published: September 29, 2022
An Updated Analysis of the Survival Endpoints of ASCENDE-RT.
Journal: International journal of radiation oncology, biology, physics
Published: February 11, 2022
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Journal: BMC cancer
Published: March 16, 2020
Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: August 01, 2019
Last Updated: 09/26/2026